Artemisinin (Artesunate) for Stage IV Cancer
Also known as: Artesunate, DHA (dihydroartemisinin), Sweet wormwood extract
An antimalarial drug with selective anti-cancer properties due to iron-dependent oxidative stress generation in iron-rich cancer cells.
Mechanism of Action
Artemisinin and its derivatives contain an endoperoxide bridge that reacts with intracellular iron (Fe2+) to generate cytotoxic free radicals. Cancer cells overexpress transferrin receptors and accumulate more iron than normal cells, making them selectively vulnerable. Additional mechanisms include ferroptosis induction, anti-angiogenesis (VEGF inhibition), and cell cycle arrest.
General mechanism: Endoperoxide-mediated free radical generation in iron-rich cells. Selective cytotoxicity via ferroptosis and ROS.
Current Evidence
Preclinical evidence across multiple cancer types. Small clinical studies in colorectal and breast cancer show promising combination effects with standard therapy. Artesunate is WHO-approved for malaria with established safety. Case reports of tumor response in combination settings.
Clinical Status: Phase I/II trials for cancer. WHO-approved for malaria. Drug repurposing studies ongoing. Available and affordable globally.
Safety Profile
Excellent safety profile from decades of antimalarial use. Neurotoxicity at very high doses in animal models. Generally well-tolerated at therapeutic doses.
Key Research Questions
- What is the optimal iron-loading strategy to enhance artemisinin's anti-cancer selectivity?
- Can artesunate be combined safely with checkpoint inhibitors?
- Which cancer types with highest iron accumulation respond best?